ID   TRRAP_HUMAN             Reviewed;        3859 AA.
AC   Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4;
DT   28-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   12-OCT-2022, entry version 210.
DE   RecName: Full=Transformation/transcription domain-associated protein;
DE   AltName: Full=350/400 kDa PCAF-associated factor;
DE            Short=PAF350/400;
DE   AltName: Full=STAF40;
DE   AltName: Full=Tra1 homolog;
GN   Name=TRRAP; Synonyms=PAF400;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8;
RA   McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.;
RT   "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc
RT   and E2F oncoproteins.";
RL   Cell 94:363-374(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344;
RP   369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820;
RP   1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726;
RP   2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND
RP   IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L;
RP   TAF10; SUPT3H; TAF12 AND TAF9.
RC   TISSUE=Fetal heart;
RX   PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9;
RA   Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J.,
RA   Nakatani Y.;
RT   "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the
RT   ATM superfamily.";
RL   Mol. Cell 2:869-875(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H;
RP   GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001;
RA   Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M.,
RA   Kundu T.K., Chait B.T., Roeder R.G.;
RT   "Human STAGA complex is a chromatin-acetylating transcription coactivator
RT   that interacts with pre-mRNA splicing and DNA damage-binding factors in
RT   vivo.";
RL   Mol. Cell. Biol. 21:6782-6795(2001).
RN   [7]
RP   IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H;
RP   TAF2; TAF4; TAF5; GCN5L2 AND TAF10.
RX   PubMed=10373431; DOI=10.1074/jbc.274.26.18285;
RA   Brand M., Yamamoto K., Staub A., Tora L.;
RT   "Identification of TATA-binding protein-free TAFII-containing complex
RT   subunits suggests a role in nucleosome acetylation and signal
RT   transduction.";
RL   J. Biol. Chem. 274:18285-18289(1999).
RN   [8]
RP   IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2.
RX   PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9;
RA   Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M.,
RA   Scully R., Qin J., Nakatani Y.;
RT   "Involvement of the TIP60 histone acetylase complex in DNA repair and
RT   apoptosis.";
RL   Cell 102:463-473(2000).
RN   [9]
RP   INTERACTION WITH GCN5L2.
RX   PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000;
RA   McMahon S.B., Wood M.A., Cole M.D.;
RT   "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5
RT   to c-Myc.";
RL   Mol. Cell. Biol. 20:556-562(2000).
RN   [10]
RP   INTERACTION WITH E2F1 AND E2F4, AND FUNCTION.
RX   PubMed=11418595; DOI=10.1074/jbc.m102067200;
RA   Lang S.E., McMahon S.B., Cole M.D., Hearing P.;
RT   "E2F transcriptional activation requires TRRAP and GCN5 cofactors.";
RL   J. Biol. Chem. 276:32627-32634(2001).
RN   [11]
RP   DOMAIN.
RX   PubMed=11445536; DOI=10.1101/gad.900101;
RA   Park J., Kunjibettu S., McMahon S.B., Cole M.D.;
RT   "The ATM-related domain of TRRAP is required for histone acetyltransferase
RT   recruitment and Myc-dependent oncogenesis.";
RL   Genes Dev. 15:1619-1624(2001).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002;
RA   Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E.,
RA   McMahon S.B.;
RT   "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP
RT   acetyltransferase complexes.";
RL   Mol. Cell. Biol. 22:5650-5661(2002).
RN   [13]
RP   IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4.
RX   PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002;
RA   Park J., Wood M.A., Cole M.D.;
RT   "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-
RT   interacting nuclear cofactor for oncogenic transformation.";
RL   Mol. Cell. Biol. 22:1307-1316(2002).
RN   [14]
RP   FUNCTION.
RX   PubMed=12743606; DOI=10.1038/sj.onc.1206376;
RA   Lang S.E., Hearing P.;
RT   "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone
RT   acetyltransferase complex.";
RL   Oncogene 22:2836-2841(2003).
RN   [15]
RP   FUNCTION.
RX   PubMed=12660246; DOI=10.1074/jbc.m211795200;
RA   Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.;
RT   "c-Myc transformation domain recruits the human STAGA complex and requires
RT   TRRAP and GCN5 acetylase activity for transcription activation.";
RL   J. Biol. Chem. 278:20405-20412(2003).
RN   [16]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE
RP   NUA4 COMPLEX.
RX   PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004;
RA   Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.;
RT   "Structural and functional conservation of the NuA4 histone
RT   acetyltransferase complex from yeast to humans.";
RL   Mol. Cell. Biol. 24:1884-1896(2004).
RN   [17]
RP   IDENTIFICATION IN STAGA COMPLEX.
RX   PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011;
RA   Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S.,
RA   Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G.,
RA   Schuele R., Takeyama K., Kato S., Tora L., Devys D.;
RT   "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination,
RT   coactivates nuclear receptors, and counteracts heterochromatin silencing.";
RL   Mol. Cell 29:92-101(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT.
RX   PubMed=17967892; DOI=10.1128/mcb.00607-07;
RA   DeRan M., Pulvino M., Greene E., Su C., Zhao J.;
RT   "Transcriptional activation of histone genes requires NPAT-dependent
RT   recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S
RT   phase transition.";
RL   Mol. Cell. Biol. 28:435-447(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [22]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.m110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF
RP   VARIANT PHE-722.
RX   PubMed=21499247; DOI=10.1038/ng.810;
RA   Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S.,
RA   Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S.,
RA   Rosenberg S.A., Samuels Y.;
RT   "Exome sequencing identifies GRIN2A as frequently mutated in melanoma.";
RL   Nat. Genet. 43:442-446(2011).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX.
RX   PubMed=24463511; DOI=10.1038/nature12922;
RA   Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M.,
RA   Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C.,
RA   Hamiche A.;
RT   "ANP32E is a histone chaperone that removes H2A.Z from chromatin.";
RL   Nature 505:648-653(2014).
RN   [30]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724;
RP   VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690;
RP   ASP-2750; GLU-2801 AND MET-2931.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [32]
RP   INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004.
RX   PubMed=30424743; DOI=10.1186/s12881-018-0711-9;
RA   Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S.,
RA   Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J.,
RA   Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.;
RT   "De novo variant of TRRAP in a patient with very early onset psychosis in
RT   the context of non-verbal learning disability and obsessive-compulsive
RT   disorder: a case report.";
RL   BMC Med. Genet. 19:197-197(2018).
RN   [33]
RP   VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037;
RP   THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866;
RP   ARG-1866; ARG-1883; LEU-1932 AND GLN-3757.
RX   PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010;
RG   CAUSES Study;
RG   Deciphering Developmental Disorders study;
RA   Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T.,
RA   Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R.,
RA   Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A.,
RA   Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T.,
RA   Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M.,
RA   Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H.,
RA   Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P.,
RA   Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J.,
RA   Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A.,
RA   Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E.,
RA   Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R.,
RA   Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N.,
RA   Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A.,
RA   Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X.,
RA   Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K.,
RA   Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R.,
RA   Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S.,
RA   Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S.,
RA   Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B.,
RA   Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y.,
RA   Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S.,
RA   Campeau P.M.;
RT   "Missense Variants in the Histone Acetyltransferase Complex Component Gene
RT   TRRAP Cause Autism and Syndromic Intellectual Disability.";
RL   Am. J. Hum. Genet. 104:530-541(2019).
RN   [34]
RP   VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN
RP   DFNA75.
RX   PubMed=31231791; DOI=10.1111/cge.13590;
RA   Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.;
RT   "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing
RT   loss.";
RL   Clin. Genet. 96:300-308(2019).
CC   -!- FUNCTION: Adapter protein, which is found in various multiprotein
CC       chromatin complexes with histone acetyltransferase activity (HAT),
CC       which gives a specific tag for epigenetic transcription activation.
CC       Component of the NuA4 histone acetyltransferase complex which is
CC       responsible for acetylation of nucleosomal histones H4 and H2A. Plays a
CC       central role in MYC transcription activation, and also participates in
CC       cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4-
CC       mediated transcription activation. Also involved in transcription
CC       activation mediated by the adenovirus E1A, a viral oncoprotein that
CC       deregulates transcription of key genes. Probably acts by linking
CC       transcription factors such as E1A, MYC or E2F1 to HAT complexes such as
CC       STAGA thereby allowing transcription activation. Probably not required
CC       in the steps following histone acetylation in processes of
CC       transcription activation. May be required for the mitotic checkpoint
CC       and normal cell cycle progression. Component of a SWR1-like complex
CC       that specifically mediates the removal of histone H2A.Z/H2AZ1 from the
CC       nucleosome. May play a role in the formation and maintenance of the
CC       auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5,
CC       ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177,
CC       ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606,
CC       ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892,
CC       ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}.
CC   -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors.
CC       Interacts directly with p53/TP53. Interacts with GCN5L2. Component of
CC       various HAT complexes. Component of the PCAF complex, at least composed
CC       of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65-
CC       alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component
CC       of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L,
CC       SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5,
CC       TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase
CC       complex which contains the catalytic subunit KAT5/TIP60 and the
CC       subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1,
CC       RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15,
CC       MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of
CC       the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L,
CC       TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core
CC       complex is associated with a subcomplex required for histone
CC       deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the
CC       BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and
CC       TRRAP, which preferentially acetylates histone H4 (and H2A) within
CC       nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1.
CC       Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431,
CC       ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108,
CC       ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863,
CC       ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177,
CC       ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892,
CC       ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287,
CC       ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738,
CC       ECO:0000269|PubMed:9885574}.
CC   -!- INTERACTION:
CC       Q9Y4A5; O15265: ATXN7; NbExp=7; IntAct=EBI-399128, EBI-708350;
CC       Q9Y4A5; P01106: MYC; NbExp=6; IntAct=EBI-399128, EBI-447544;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863,
CC       ECO:0000269|PubMed:9708738}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y4A5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103;
CC   -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT
CC       complexes, and the MYC-dependent transactivation. Although it is
CC       strongly related to the PI3/PI4-kinase family, it lacks the typical
CC       motifs that constitute the catalytic site of PI3/PI4-kinase proteins,
CC       and lacks such activity. {ECO:0000269|PubMed:11445536}.
CC   -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in
CC       cutaneous malignant melanoma, suggesting that TRRAP may play a role in
CC       the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}.
CC   -!- DISEASE: Developmental delay with or without dysmorphic facies and
CC       autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental
CC       disorder apparent from infancy or early childhood. Some patients
CC       present with intellectual disability and renal, cardiac, genitourinary
CC       systems, as well as structural brain abnormalities. In some cases, the
CC       phenotype is less severe, has no systemic involvement and is
CC       characterized by autism spectrum disorder and/or intellectual
CC       disability, sometimes associated with epilepsy. Affected individuals
CC       manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743,
CC       ECO:0000269|PubMed:30827496}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form
CC       of non-syndromic deafness characterized by late-onset hearing loss that
CC       involves mid and high frequencies, and progresses to encompass all
CC       frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF076974; AAD09420.1; -; mRNA.
DR   EMBL; AF110377; AAD04629.1; -; mRNA.
DR   EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC004991; AAC27675.2; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76694.1; -; Genomic_DNA.
DR   EMBL; CH236956; EAL23887.1; -; Genomic_DNA.
DR   CCDS; CCDS5659.1; -. [Q9Y4A5-2]
DR   CCDS; CCDS59066.1; -. [Q9Y4A5-1]
DR   PIR; T02632; T02632.
DR   RefSeq; NP_001231509.1; NM_001244580.1. [Q9Y4A5-1]
DR   RefSeq; NP_003487.1; NM_003496.3. [Q9Y4A5-2]
DR   SMR; Q9Y4A5; -.
DR   BioGRID; 113900; 227.
DR   ComplexPortal; CPX-6802; SAGA complex, KAT2B variant.
DR   ComplexPortal; CPX-900; SAGA complex, KAT2A variant.
DR   ComplexPortal; CPX-903; TFTC histone acetylation complex.
DR   ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex.
DR   ComplexPortal; CPX-989; PCAF histone acetylase complex.
DR   CORUM; Q9Y4A5; -.
DR   DIP; DIP-28149N; -.
DR   IntAct; Q9Y4A5; 82.
DR   MINT; Q9Y4A5; -.
DR   STRING; 9606.ENSP00000352925; -.
DR   iPTMnet; Q9Y4A5; -.
DR   MetOSite; Q9Y4A5; -.
DR   PhosphoSitePlus; Q9Y4A5; -.
DR   BioMuta; TRRAP; -.
DR   DMDM; 116242829; -.
DR   EPD; Q9Y4A5; -.
DR   jPOST; Q9Y4A5; -.
DR   MassIVE; Q9Y4A5; -.
DR   MaxQB; Q9Y4A5; -.
DR   PaxDb; Q9Y4A5; -.
DR   PeptideAtlas; Q9Y4A5; -.
DR   PRIDE; Q9Y4A5; -.
DR   ProteomicsDB; 86142; -. [Q9Y4A5-1]
DR   ProteomicsDB; 86143; -. [Q9Y4A5-2]
DR   Antibodypedia; 16027; 188 antibodies from 22 providers.
DR   DNASU; 8295; -.
DR   Ensembl; ENST00000355540.7; ENSP00000347733.3; ENSG00000196367.14. [Q9Y4A5-2]
DR   Ensembl; ENST00000359863.8; ENSP00000352925.4; ENSG00000196367.14. [Q9Y4A5-1]
DR   GeneID; 8295; -.
DR   KEGG; hsa:8295; -.
DR   UCSC; uc003upp.3; human. [Q9Y4A5-1]
DR   CTD; 8295; -.
DR   DisGeNET; 8295; -.
DR   GeneCards; TRRAP; -.
DR   HGNC; HGNC:12347; TRRAP.
DR   HPA; ENSG00000196367; Low tissue specificity.
DR   MalaCards; TRRAP; -.
DR   MIM; 603015; gene.
DR   MIM; 618454; phenotype.
DR   MIM; 618778; phenotype.
DR   neXtProt; NX_Q9Y4A5; -.
DR   OpenTargets; ENSG00000196367; -.
DR   Orphanet; 90635; Autosomal dominant non-syndromic sensorineural deafness type DFNA.
DR   PharmGKB; PA37020; -.
DR   VEuPathDB; HostDB:ENSG00000196367; -.
DR   eggNOG; KOG0889; Eukaryota.
DR   GeneTree; ENSGT00390000017961; -.
DR   InParanoid; Q9Y4A5; -.
DR   OrthoDB; 7189at2759; -.
DR   PhylomeDB; Q9Y4A5; -.
DR   TreeFam; TF106414; -.
DR   PathwayCommons; Q9Y4A5; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SignaLink; Q9Y4A5; -.
DR   SIGNOR; Q9Y4A5; -.
DR   BioGRID-ORCS; 8295; 742 hits in 1119 CRISPR screens.
DR   ChiTaRS; TRRAP; human.
DR   GenomeRNAi; 8295; -.
DR   Pharos; Q9Y4A5; Tbio.
DR   PRO; PR:Q9Y4A5; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9Y4A5; protein.
DR   Bgee; ENSG00000196367; Expressed in ventricular zone and 154 other tissues.
DR   ExpressionAtlas; Q9Y4A5; baseline and differential.
DR   Genevisible; Q9Y4A5; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000786; C:nucleosome; IDA:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000124; C:SAGA complex; IDA:UniProtKB.
DR   GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB.
DR   GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB.
DR   GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0016573; P:histone acetylation; NAS:UniProtKB.
DR   GO; GO:0016578; P:histone deubiquitination; IDA:UniProtKB.
DR   GO; GO:0043968; P:histone H2A acetylation; IDA:UniProtKB.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:ComplexPortal.
DR   GO; GO:0043967; P:histone H4 acetylation; IDA:UniProtKB.
DR   GO; GO:0035521; P:monoubiquitinated histone deubiquitination; IDA:ComplexPortal.
DR   GO; GO:0035522; P:monoubiquitinated histone H2A deubiquitination; IDA:ComplexPortal.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IC:ComplexPortal.
DR   GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal.
DR   GO; GO:0042981; P:regulation of apoptotic process; IC:ComplexPortal.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal.
DR   GO; GO:0006282; P:regulation of DNA repair; IC:ComplexPortal.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:2000779; P:regulation of double-strand break repair; IC:ComplexPortal.
DR   GO; GO:0043484; P:regulation of RNA splicing; IC:ComplexPortal.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR033317; TRA1/TRRAP.
DR   PANTHER; PTHR11139:SF1; PTHR11139:SF1; 2.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Alternative splicing; Autism spectrum disorder;
KW   Chromatin regulator; Deafness; Direct protein sequencing; Disease variant;
KW   Intellectual disability; Isopeptide bond; Non-syndromic deafness; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   CHAIN           2..3859
FT                   /note="Transformation/transcription domain-associated
FT                   protein"
FT                   /id="PRO_0000088851"
FT   DOMAIN          2692..3275
FT                   /note="FAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534"
FT   DOMAIN          3500..3823
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   DOMAIN          3827..3859
FT                   /note="FATC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534,
FT                   ECO:0000255|PROSITE-ProRule:PRU00535"
FT   REGION          491..541
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2010..2388
FT                   /note="Interaction with TP53"
FT                   /evidence="ECO:0000269|PubMed:12138177"
FT   REGION          2023..2044
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2543..2578
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3506..3512
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          3687..3695
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          3707..3732
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   MOTIF           2047..2062
FT                   /note="Bipartite nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        491..525
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2028..2044
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   MOD_RES         1628
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2051
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2077
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         3078
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CROSSLNK        2543
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1492..1509
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9708738"
FT                   /id="VSP_009102"
FT   VAR_SEQ         3001..3012
FT                   /note="GKPTWSGMHSSS -> A (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9708738"
FT                   /id="VSP_009103"
FT   VARIANT         171
FT                   /note="R -> C (in DFNA75; unknown pathological
FT                   significance; dbSNP:rs200157211)"
FT                   /evidence="ECO:0000269|PubMed:31231791"
FT                   /id="VAR_083794"
FT   VARIANT         394
FT                   /note="D -> N (in DFNA75; unknown pathological
FT                   significance; dbSNP:rs1554407965)"
FT                   /evidence="ECO:0000269|PubMed:31231791"
FT                   /id="VAR_083795"
FT   VARIANT         722
FT                   /note="S -> F (found in a cutaneous malignant melanoma
FT                   sample; somatic mutation; induces cell transformation and
FT                   confers resistance to apoptosis; dbSNP:rs147405090)"
FT                   /evidence="ECO:0000269|PubMed:21499247"
FT                   /id="VAR_067754"
FT   VARIANT         805
FT                   /note="L -> F (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs1562940289)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082969"
FT   VARIANT         860
FT                   /note="F -> L (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082970"
FT   VARIANT         878
FT                   /note="R -> L (in dbSNP:rs17161510)"
FT                   /id="VAR_028359"
FT   VARIANT         893
FT                   /note="R -> C (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041658"
FT   VARIANT         893
FT                   /note="R -> L (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082971"
FT   VARIANT         1031
FT                   /note="I -> M (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082972"
FT   VARIANT         1035
FT                   /note="R -> Q (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082973"
FT   VARIANT         1037
FT                   /note="S -> R (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082974"
FT   VARIANT         1043
FT                   /note="A -> T (in DEDDFA; dbSNP:rs1562945106)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082975"
FT   VARIANT         1070
FT                   /note="S -> G (in dbSNP:rs55920979)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041659"
FT   VARIANT         1104
FT                   /note="E -> G (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082976"
FT   VARIANT         1106
FT                   /note="E -> K (in DEDDFA; dbSNP:rs1584324956)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082977"
FT   VARIANT         1111
FT                   /note="G -> W (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082978"
FT   VARIANT         1159
FT                   /note="G -> R (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082979"
FT   VARIANT         1669
FT                   /note="R -> H (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs373632999)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041660"
FT   VARIANT         1724
FT                   /note="R -> H (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs782203759)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041661"
FT   VARIANT         1859
FT                   /note="R -> C (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082980"
FT   VARIANT         1866
FT                   /note="W -> C (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs1562957576)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082981"
FT   VARIANT         1866
FT                   /note="W -> R (in DEDDFA; dbSNP:rs1562957569)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082982"
FT   VARIANT         1883
FT                   /note="G -> R (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082983"
FT   VARIANT         1925
FT                   /note="A -> V (in dbSNP:rs56197298)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041662"
FT   VARIANT         1932
FT                   /note="P -> L (in DEDDFA; unknown pathological
FT                   significance; also found in a colorectal adenocarcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:30827496"
FT                   /id="VAR_041663"
FT   VARIANT         1947
FT                   /note="R -> L (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041664"
FT   VARIANT         2004
FT                   /note="R -> Q (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs1562959030)"
FT                   /evidence="ECO:0000269|PubMed:30424743"
FT                   /id="VAR_082984"
FT   VARIANT         2139
FT                   /note="W -> G (in dbSNP:rs34185633)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041665"
FT   VARIANT         2302
FT                   /note="R -> W (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs528967912)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041666"
FT   VARIANT         2433
FT                   /note="S -> G (in dbSNP:rs35634065)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041667"
FT   VARIANT         2690
FT                   /note="P -> L (in a lung large cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs753661271)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041668"
FT   VARIANT         2750
FT                   /note="E -> D (in dbSNP:rs55755466)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:31231791"
FT                   /id="VAR_041669"
FT   VARIANT         2801
FT                   /note="K -> E (in dbSNP:rs56341061)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041670"
FT   VARIANT         2931
FT                   /note="T -> M (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs1294404368)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041671"
FT   VARIANT         3757
FT                   /note="R -> Q (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs987263983)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082985"
FT   CONFLICT        660
FT                   /note="E -> D (in Ref. 2; AAD04629)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   3859 AA;  437600 MW;  391E467C0047B00B CRC64;
     MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST
     FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF
     LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP
     ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK
     LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE
     LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL
     IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC
     KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV
     EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT
     FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL
     DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE
     RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS
     VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL
     PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT
     LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG
     SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR
     RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ
     ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE
     ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY
     IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN
     GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA
     MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP
     RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP
     QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL
     TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC
     PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK
     FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA
     QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH
     RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI
     PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE
     GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR
     LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV
     RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH
     LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN
     SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF
     LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN
     QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM
     SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS
     NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM
     EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM
     TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE
     VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS
     ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS
     EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL
     SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH
     NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM
     WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW
     EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM
     AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI
     IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ
     GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI
     LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE
     FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI
     TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT
     CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC
     SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD
     AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF
     TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI
     PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR
     REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR
     CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP
     NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD
     LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA
     WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA
     AANSLDNLCR MDPAWHPWL
//
